Possible inhibition of hydroxy methyl glutaryl CoA reductase activity by nicotinic acid and ergosterol: as targeting for hypocholesterolemic action by Moselhy, Said S. et al.
Possible inhibition of  hydroxy methyl glutaryl CoA reductase activity 
by nicotinic acid and ergosterol: as targeting for hypocholesterolemic action.
Said S. Moselhy1,2 ,3,6, Kamal IH1,6,Taha A. Kumosani1,2,4, Huwait EA1,2,4   
1. Biochemistry Department, Faculty of  science, King Abdulaziz University.
2. Experimental biochemistry unit, King Fahad Medical Research center (KFMRC).
3. Bioactive Natural Products Research Group.
4. Production of  bio-products for industrial applications Research group, 
5Vitamin D Research group  King Abdulaziz University P.O. Box 21424, Jeddah, Saudi Arabia.
6. Biochemistry department, faculty of  science, Ain Shams University, Cairo, Egypt.
Abstract
Objective: Coronary artery diseases including atherosclerosis is considered as commonest problem worldwide. Ergosterols 
are the main components of  vegetable oils and nuts. The objective of  this study was to evaluate the potential hypoplipidemic 
and  hypocholesterolemic effects of  ergosterol in combination with niacin in rats fed high fat diet (HFD). 
Methods: Eighty male albino rats were included in this study divided into two main groups: Group I: Normal rats fed stand-
ard diet treated with either niacin (8.5 mg /kg b.w) or ergosterol (100 mg/Kg b.w) or both. Group II; rats fed HFD treated 
with either niacin (8.5 mg /kg b.w) or ergosterol (100 mg/Kg b.w) or both The feeding and treatment lasted for 8 weeks. 
Results: A significant elevation in the levels of  total cholesterol, triacylglycerol, VLDL-c, LDL-c and atherogenic factor 
(p<0.001) in rats fed on HFD compared with normal control while HDL-c was significantly reduced in HFD rats compared 
with control group. Supplementation of  diet with niacin or ergosterol or combined exerts improvement in the studied pa-
rameters by lowering triacylglycerol, total cholesterol, LDL-c and atherogenic factor and elevate HDL-c near to the value 
of  control. Niacin combined with ergosterol were effective in the reduction of   hydroxy methyl glutaryl-CoA reducatase 
(HMGCoA)  compared with control (p<0.001). The combined effect was more potent than individual alone. 
Conclusion: Utilization of  niacin and ergosterol may prevent the hypercholesterolemia and incidence of  coronary heart 
diseases. These functional foods act as nutriceutical as dyslipidemics.   
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Introduction
Cholesterol is non-calorigenic nutrient due to lack of  
enzymes that metabolize it. It is an essential for plasma 
membranes structure and formation of  lipoproteins, 
aldosterone, bile salts, and cholicalciferol1.Cholesterol 
in the body may be exogenous (from diet) or endoge-
nous which synthesized from active acetate in the liver, 
testis, and ovary and controlled by the key enzyme hy-
droxy methyl glutaryl-CoA reductase (HMGCoA Rase). 
Blood cholesterol level determined by the balance be-
tween its  rate of  synthesis and rate of  excretion. The 
liver is the only organ can eliminate the cholesterol by 
excretion via the bile2.
Coronary artery diseases (CAD) including atheroscle-
rosis considered as the commonest cause of  death 
worldwide. Other risk factors including smoking, hy-
pertension, lifestyle, diabetes and fast foods. Hypercho-
lesterolemia especially elevated LDL-c and decreased 
HDL-c are the most valuable markers for CAD3. Ath-
erosclerosis is indicated by the appearance of  initial 
changes known as plaques. These plaques are made of  
lipid cores (cholesterol) surrounded by fibroid caps5. A 
clear cut correlation was found between dietary cho-
lesterol and CAD by several previous studies in animal 
models and human. The risk for CAD is approximately 
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Nicotinic acid or niacin is is converted to important 
co-enzymes NAD+, or NADP+. These co-enzymes 
act as a hydrogen carrier involved in oxidation reduc-
tion reactions during metabolism of  macromolecules as 
carbohydrate, lipids and proteins5.
Ergosterols are the main components of  vegetable oils, 
nuts, cereal products, fruit and berries. The common 
types are β-sitosterol, campesterol and stigmasterol6. 
Phytosterol was found to act as anticancer and antiox-
idant agent.  It was found in several studies that intake 
of  foods as margarine or yoghurt supplemented with 
plant stanol lower serum total cholesterol and LDL-c. 
This is the principle  hypocholesterolemic effect of  
drugs and exert a significance effect  in lowering CAD7.
There are different hypocholestrolemic agents available, 
these drugs act by different mechanisms. Efficacy re-
lies on the lipid level of  the subjects. These drugs have 
adverse effects varied from one to another. Thus, re-
searches are promising to explore novel drugs that are 
more efficacies and more safe.
This study was designed to evaluate the potential hyo-
plipidemic and hypocholesterolemic effect of  ergoster-
ol in combination with nicotinic acid in rats. For this 





This study was carried out on a total of  80 adult male al-
bino rats weighing 100–120 g. The animals were housed 
in steel cages and left for one week before starting the 
experiment. The commercial diet supplemented with 2 
% cholesterol, and 0.4% sodium cholate considered as 
high cholesterol diet8.The handling of  animals accord-
ing to ethical committee of  the university.
Rats were grouped into two main groups (each 40 rats) 
as following: Group I: normal rats fed a standard diet 
and divided into 4 subgroups: Group Ia; normal un-
treated.  Group Ib: rats treated orally with niacin (8.5 
mg /kg b.w). Group Ic: rats treated orally with ergos-
terol (100 mg/Kg b.w.). Group Id. rats treated orally 
with niacin (8.5 mg /kg b.w.) and ergosterol (100 mg/
Kg b.w.). Group II: rats fed high  HFD (1% choles-
terol (w/w) and 0.2% sodium cholate (w/w) were well 
mixed with the finely-ground commercial diet) subdi-
vided into 4 subgroups. Group IIa ; HFD untreated. 
Group IIb: HFD  treated orally with niacin (8.5 mg /
kg b.w.)  Group IIc: HFD rats treated orally with ergos-
terol (80 mg/Kg b.w). Group IId : HFD treated orally 
with niacin (8.5 mg /kg b.w.) and ergosterol (80 mg/Kg 
b.w.).The doses of  ergosterol and niacin will given ac-
cording to Takaku et al12.Treatment was started on the 
day starting feeding high cholesterol and continued for 
8 weeks. Rat were fasted for 12hr and anesthetized with 
10% thiopental. Blood samples were collected and sera 
were separated by centrifugation and stored at -80°C 
until analysis. Liver was removed, rinsed from blood. 
Part of  it was placed in sulphuric acid for total lipid 
assay and the remainder of  liver will stored in at -80°C 
until analysis.
Biochemical assays
Serum total cholesterol, triacylglycerol, total lipid lipo-
proteins (VLDL-c, LDL-c and HDL-c) were  estimat-
ed  by colorimetric methods using kits from BIOLINE 
company (UK). Atherogenic index was calculated as 
following.
Atherogenic index = LDL + VLDL/ HDL
Determination of  liver microsomal HMGCoA re-
ductase
One gram of  liver was placed in 5 ml cold buffer (-4°C) 
at pH 7.4. The buffer contained 0.1 M triethanolamine. 
HCl, 0.02 M EDTA, and 2.0mM dithiothreitol, homog-
enized  using glass homogenizer. The homogenate was 
centrifuged for 10 min at 12,000 g to remove mito-
chondria. Supernatant was centrifuged at 20,000 g for 
30 min. The microsomes obtained were used for the as-
say of  protein concentration and  HMGCoA reductase. 
For assay 0.5-1 mg of  microsomal protein, 100 nmoles 
of  HMG CoA, and 2 μmoles of  NADPH, 2 units of  
glucose-6-phosphate dehydrogenase, and 3 μmoles of  
glucose-6-phosphate. These components are added to 
0.8 ml of  0.1 M triethanolamine-0.02 M EDTAbuffer 
at pH 7.4 without dithiothreitol. The concentration of  
monothiol is determined by reacting DTNB with the 
reaction mixture in a cuvette placed in a recording spec-
trophotometer9.
The unit of  HMGCoA reductase is defined as the mi-
cromole of  mevalonate produced per unit of  enzyme 
per second.
Statistical analysis
Data will be expressed as means ± SD and t-test, p-val-
ue and Man-watany correlation will performed using 
SPSS version12. 
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Results
Table (1) revealed the impact of  niacin and ergoster-
ol on normal rats fed normal diet. It was found that, 
normal rats supplemnteed with niacin, ergosterol or 
combined showed a significant reduction in lipid pro-
file including TG, total cholesterol and LDL-c while  a 
significant increase in  HDL-c compared with control 
group (p<0.01).   
Table (1): Serum levels of total-cholesterol, triacylglycerol, HDL-c, LDL-c, VLDL-c and 


























































































































             HFD: High fat diet  p: compared with control group. p*: compared with HFD   N.S.: non significan      
            p<0.05 was considered as significant   Nia; Niacin   ERG: ergosterol 
In table (2), Rats fed high fat diet showed that, a sig-
nificant elevation in the levels of  total cholesterol, tri-
acylglycerol, , VLDL-c, LDL-c and atherogenic factor 
(p<0.001) in rats fed on HFD compared with normal 
control while HDL-c was  significantly reduced. Sup-
plementation of  diet with niacin  or ergosterol or com-
bined  exerts improvement in the studied parameters 
by lowering triacylglycerol, total cholesterol, LDL-c and 
atherogenic factor  and elevating HDL-c  till it reached 
near to the value of  control  as compared with HFD 
fed rats (p<0.001).    
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Table (1): Serum levels of total-cholesterol, triacylglycerol, HDL-c, LDL-c, VLDL-c and atherogenic factor in 
hypercholesterolemic rats treated with niacin and ergosterol (Mean +SD) 
 
Groups 



















































































































HFD: High fat diet p: compared with control group.p*: compared with HFD  N.S.: non significan  p<0.05 was considered as significantNia; Niacin    ERG: ergosterol 
Results obtained in Fig 1. indicated that niacin , ergos-
terol and combined were effective in the reduction of  
HMGCoA reductase  compared with control (p<0.001). 
The combined effect was more potent than individual 
alone.
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HFD: High fat diet   p: compared with control group.  p*: compared with HFD     NS: non signifficant   p< 0.05 was considered a 
significant  Nia: Niacin  ERG:ergosterol  
Table (2): Serum levels of total-cholesterol, triacylglycerol, L-c, LDL-c, VLDL-c and atherogenic factor in 
hypercholesterolemic rats treated with niacin and ergosterol (Mean +SD) 
Group Ia; normal untreated.  Group Ib: normal with niacin (8.5 mg /kg b.w). Group Ic: normal 
with ergosterol (100 mg/Kg b.w). Group Id. normal with niacin (8.5 mg /kg b.w) and ergosterol 
(100 mg/Kg b.w).Group IIa; HFD untreated. Group IIb: HFD with niacin (8.5 mg /kg 
b.w) Group IIc: HFD rats with ergosterol (80 mg/Kg b.w).Group IId: HFD with niacin (8.5 mg 
/kg b.w) and ergosterol (80 mg/Kg b.w). 
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Discussion
The HMG CoA reductase catalyses the rate limiting step 
in cholesterol synthesis10. The activity of  HMG CoA 
reductase is regulated by the nutritional and hormonal 
state of  animals. Feedback inhibition of  cholesterol 
formation is mediated by the activity of  HMG CoA 
reductase. Many chemically synthesized compounds 
called statins, have also been developed as effective 
cholesterol lowering agents through the inhibition of  
HMG CoA reductase. However, most hypocholester-
olemic agents have been found to possess adverse ef-
fects, including rashes, gastrointestinal, hyperuricemia, 
hyperglycemia11.
In the present study supplementing rats with niacin o, 
LDL-c and TG compared to control rats. Niacin was 
found to lower plasma total cholesterol and triglyceride 
levels by lowering VLDL-c and LDL-c levels12.  On the 
other hand it elevates HDL-c levels. Plant sterol pos-
sesses the ability to lower effect in a wide range of  food 
products. The cholesterol and LDL-C lowering effect 
of  ergosterol as well as safety of  daily consumption of  
plant source was in accordance with different studies13. 
The most recent is evidence that intakes of  ergosterol 
result in an enhanced decrease in LDL-c level compara-
ble to that obtained by statins. The lowering of  LDL-C 
was higher and is feasible as a range of  food products 
are commercially available for consumption. LDL-c 
lowering effect contributes to beneficial effects in re-
ducing the risk of  cardiovascular diseases14. The de-
crease in the LDL-c level due to consumption of  plant 
stanols in high doses (about 9 g) is of  similar magnitude 
to that achieved by drugs lowering cholesterol via partly 
blocking cholesterol absorption15.
Changes in HMG-CoA reductase activity are accom-
panied to changes in the rate of  cholesterol synthesis, 
suggesting the inhibition of  HMG-CoA reductase is ef-
fective in lowering plasma cholesterol16.
On the basis of  the present study, a significant LDL-c 
lowering effect can be done by a dietary supplemen-
tation of  ergosterol. However, there was a dose-range 
effect of  plant sterols and stanols on serum LDL-c 
lowering and it is reported that plant stanols showed a 
continuous dose–response in serum LDL-c lowering, 
whereas no further serum LDL-c was apparent with 
plant sterols at daily intakes exceeding 2 g/day17,18.
Three of  the studies with high daily plant stanol in-
take also reported serum plant stanol and sterol con-
centrations. Assmann et al.,19 demonstrated that a dai-
ly intake of  8.8 g plant stanols decreased cholesterol 
absorption markers .Similarly, Mensink et al.,20 showed 
continuous decrease in plasma sitosterol and campes-
terol concentrations with 3, 6 and 9 g intakes of  plant 
stanols in comparison to controls. With increasing plant 
stanol intake, the cholesterol absorption was reduced21. 
Nguyen22 reported a 40% lower campesterol and 50% 
lower sitosterol levels after daily consumption of  10 g 
of  plant stanols.
The present study showed the role of  niacin combined 
with ergosterol  in reducing the cholesterol level  by in-
hibiting the HMG CoA reductase activity. This finding 
can result in developing a nutraceutical agent and can 
be used in management of  disorders of  cholesterol for 
controlling the dyslipidemia. 
Conclusion
Daily utilization of  niacin and ergosterol may protect 
against hypercholesterolemia and decrease incidence of  
coronary heart diseases. These functional foods act as 
nutriceutical as dyslipidemics.  
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